A Correlation Between the In Vitro Drug Toxicity of Drugs to Cell Lines That Express Human P450s and Their Propensity to Cause Liver Injury in Humans
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drug toxicity to T-antigen-immortalized human liver epithelial (THLE) cells stably transfected with plasmid vectors that encoded human cytochrome P450s 1A2, 2C9, 2C19, 2D6, or 3A4, or an empty plasmid vector (THLE-Null), was investigated. An automated screening platform, which included 1% dimethyl sulfoxide (DMSO) vehicle, 2.7% bovine serum in the culture medium, and assessed 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction, was used to evaluate the cytotoxicity of 103 drugs after 24h. Twenty-two drugs caused cytotoxicity to THLE-Null cells, with EC₅₀ ≤ 200 μM; 21 of these drugs (95%) have been reported to cause human liver injury. Eleven drugs exhibited lower EC₅₀ values in cells transfected with CYP3A4 (THLE-3A4 cells) than in THLE-Null cells; 10 of these drugs (91%) caused human liver injury. An additional 8 drugs, all of which caused human liver injury, exhibited potentiated THLE-3A4 cell toxicity when evaluated using a manual protocol that included 0.2% or 1% DMSO, but not bovine serum. Fourteen of the drugs that exhibited potentiated THLE-3A4 cell toxicity are known to be metabolized by P450s to reactive intermediates. These drugs included troglitazone, which was shown to undergo metabolic bioactivation and covalent binding to proteins in THLE-3A4 cells. A single drug (rimonabant) exhibited marked THLE cell toxicity but did not cause human liver injury; this drug had very low reported plasma exposure. These results indicate that evaluation of toxicity to THLE-Null and THLE-3A4 cell lines during drug discovery may aid selection of drugs with reduced propensity to cause drug-induced liver injury and that consideration of human exposure is required to enhance data interpretation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, few of the models contain the full complement and functionality of metabolic enzymes and transporters present in human hepatocytes in vivo (Gustafsson et al. 2014; Wilkening and Bader 2003), which is also true with plated primary human hepatocytes (PHH) that rapidly loose liver phenotype and CYP450 activity in traditional monolayer cultures (Rodriguez-Antona et al. 2002).”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Gustafsson et al. 2014
Citations
Cites
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 479
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 462
Self-citationThe significance of mitochondrial toxicity testing in drug development
Dykens, J. A., & Will, Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.013 · Cited by 416
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Self-citationKassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000180q · Cited by 311
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 251
Pfeifer, A. M., Cole, K. E., Smoot, D. T., Weston, A., Groopman, J. D., Shields, P. G., Vignaud, J. M., Juillerat, M., Lipsky, M. M., & Trump, B. F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5123 · Cited by 242
Mace, K. (1997) · Carcinogenesis · doi:10.1093/carcin/18.7.1291 · Cited by 224
Thompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, B., Stahl, S., Foster, A. J., et al. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300091x · Cited by 213
Self-citationOhyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00134.x · Cited by 190
Easterbrook, J. D., Lu, C., Sakai, Y., & Li, A. P. (2001) · PubMed · Cited by 190
New Technologies and Screening Strategies for Hepatotoxicity: Use of In Vitro Models
Dambach, D. M., Andrews, B. A., & Moulin, F. (2005) · Toxicologic Pathology · doi:10.1080/01926230590522284 · Cited by 177
Sanmartín‐Suárez, C., Soto‐Otero, R., Sánchez‐Sellero, I., & Méndez‐Álvarez, E. (2010) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.10.004 · Cited by 175
Iverson, S. L., & Uetrecht, J. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002029 · Cited by 171
Maggs, J. L., Williams, D. P., Pirmohamed, M., & Park, B. K. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12206-4 · Cited by 128
Sakatis, M. Z., Reese, M. J., Harrell, A. W., Taylor, M. A., Baines, I. A., Chen, L., Bloomer, J. C., Yang, E. Y., Ellens, H. M., Ambroso, J. L., et al. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300075j · Cited by 121
The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells
Zahno, A., Brecht, K., Morand, R., Maseneni, S., Török, M., Lindinger, P. W., & Krähenbühl, S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.11.002 · Cited by 117
Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
Thompson, R. A., Isin, E. M., Li, Y., Weaver, R. J., Weidolf, L. O. G., Wilson, I. D., Claesson, A., Page, K., Dolgos, H., & Kenna, J. G. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.11.002 · Cited by 104
Self-citationThe mechanism of bioactivation and antigen formation of amodiaquine in the rat
Harrison, A. C., Kitteringham, N. R., Clarke, J. B., & Park, B. K. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90198-r · Cited by 103
Vignati, L., Turlizzi, E., Monaci, S., Grossi, P., de Kanter, R., & Monshouwer, M. (2005) · Toxicology · doi:10.1016/j.tox.2005.08.003 · Cited by 98
Alvarez‐Sánchez, R., Montavon, F., Härtung, T., & Pähler, A. (2006) · Chemical Research in Toxicology · doi:10.1021/tx050353h · Cited by 96
Kaplowitz, N. (2002) · CRC Press eBooks · doi:10.1201/b15279 · Cited by 95
Tolosa, L., Gómez‐Lechón, M. J., Pérez-Cataldo, G., Castell, J. V., & Donato, M. T. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1012-x · Cited by 91
Animal models of idiosyncratic drug-induced liver injury—Current status
Roth, R. A., & Ganey, P. E. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2011.575765 · Cited by 80
Barcelo, S., Macé, K., Pfeifer, A. M. A., & Chipman, J. K. (1998) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00288-1 · Cited by 75
Cell based approaches for evaluation of drug-induced liver injury
Greer, M. L., Barber, J., Eakins, J. A., & Kenna, J. G. (2009) · Toxicology · doi:10.1016/j.tox.2009.08.007 · Cited by 73
Self-citationWen, B., & Zhou, M. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.05.014 · Cited by 61
Development of a Highly Sensitive Cytotoxicity Assay System for CYP3A4-Mediated Metabolic Activation
Hosomi, H., Fukami, T., Iwamura, A., Nakajima, M., & Yokoi, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037077 · Cited by 58
Benbow, J. W., Aubrecht, J., Banker, M. J., Nettleton, D. O., & Aleo, M. D. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.05.016 · Cited by 55
Rodriguez, R. J., & Buckholz, C. J. (2003) · Xenobiotica · doi:10.1080/0049825031000072243 · Cited by 54
Iwamura, A., Fukami, T., Hosomi, H., Nakajima, M., & Yokoi, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037259 · Cited by 48
CYP2D6 is involved in O-demethylation of diltiazem
Molden, E., Åsberg, A., & Christensen, H. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000182 · Cited by 33
Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Pachkoria, K., Lucena, M. I., Molokhia, M., Cueto-Galán, R., Carballo, A. S., Carvajal, A., & Andrade, R. J. (2007) · Current Drug Safety · doi:10.2174/157488607780598287 · Cited by 29
Grime, K., Webborn, P. J. H., & Riley, R. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021055 · Cited by 27
Coulet, M., Dacasto, M., Eeckhoutte, C., Larrieu, G., Sutra, J. F., Alvinerie, M., Macé, K., Pfeifer, A., & Galtier, P. (1998) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1998.tb00946.x · Cited by 26
Foster, A. J., Prime, L. H., Gustafsson, F., Temesi, D. G., Isin, E. M., Midlöv, J., Castagnoli, N. J., & Kenna, J. G. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300418w · Cited by 26
Self-citationSoltanpour, Y., Hilgendorf, C., Ahlström, M. M., Foster, A. J., Kenna, J. G., Petersen, A., & Ungell, A.-L. B. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045815 · Cited by 20
Self-citationHigh Expression of Human CYP2C in Immortalized Human Liver Epithelial Cells
Bort, R., Castell, J. V., Pfeifer, A., Gómez-Lechón, M. J., & Macé, K. (1999) · Toxicology in Vitro · doi:10.1016/s0887-2333(99)00069-7 · Cited by 13
Development of a whole‐cell screening system for evaluation of the human CYP1A2‐mediated metabolism
Chu, C., Pan, K., Yao, H., & Hsu, J. T. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23256 · Cited by 13
Cited by
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“2008), or cell viability assessment in SV-40 transformed human liver epithelial (THLE) cells (Dambach et al. 2005; Gustafsson et al. 2014).”
BackgroundInfluentialSelf-citationCompetency of different cell models to predict human hepatotoxic drugs
Gómez-Lechón, M. J., Tolosa, L., Conde, I., & Donato, M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967680 · Cited by 199
“Such THLE-based screenings have shown high specificity and acceptable sensitivity to discriminate between drugs reported as being hepatotoxic, or not, to humans [82,83].”
BackgroundMethodInfluentialVorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability
Hendriks, D. F. G., Fredriksson Puigvert, L., Messner, S., Mortiz, W., & Ingelman-Sundberg, M. (2016) · Scientific Reports · doi:10.1038/srep35434 · Cited by 156
Metadata
- Authors
- Gustafsson, F., Foster, A. J., Sarda, S., Bridgland-Taylor, M. H., & Kenna, J. G.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-01
- Volume
- 137
- Issue
- 1
- Pages
- 189-211
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2145394548
- Cited by
- 77
- References
- 40
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 7 · 2018: 9 · 2017: 13 · 2016: 13 · 2015: 9 · 2014: 5 · 2013: 1
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nestec
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- drug-induced liver injury, hepatotoxicity, human cytochrome P450, CYP3A4, cytotoxicity, drug metabolism, reactive metabolites, troglitazone, rimonabant, plasma exposure
- MeSH terms
- Biological Assay, Biotransformation, Cell Line, Cell Survival, Cytochrome P-450 Enzyme System, Dose-Response Relationship, Drug, Epithelial Cells, Humans, Liver, Risk Factors, Transfection, Risk Assessment, Toxicity Tests, Inhibitory Concentration 50, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.